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Background: Human rhinovirus (HRV) triggers exacerbations of asthma and chronic obstructive pulmonary disease
(COPD). Cigarette smoking is the leading risk factor for the development of COPD and 25% of asthmatics smoke.
Smoking asthmatics have worse symptoms and more frequent hospitalizations compared to non-smoking
asthmatics. The degree of neutrophil recruitment to the airways correlates with disease severity in COPD and
during viral exacerbations of asthma. We have previously shown that HRV and cigarette smoke, in the form of
cigarette smoke extract (CSE), each induce expression of the neutrophil chemoattractant and activator, CXCL8, in
human airway epithelial cells. Additionally, we demonstrated that the combination of HRV and CSE induces
expression of levels of CXCL8 that are at least additive relative to induction by each stimulus alone, and that
enhancement of CXCL8 expression by HRV+CSE is regulated, at least in part, via mRNA stabilization. Here we further
investigate the mechanisms by which HRV+CSE enhances CXCL8 expression.
Methods: Primary human bronchial epithelial cells were cultured and treated with CSE alone, HRV alone or the
combination of the two stimuli. Stabilizing/destabilizing proteins adenine/uridine-rich factor-1 (AUF-1), KH-type
splicing regulatory protein (KHSRP) and human antigen R (HuR) were measured in cell lysates to determine
expression levels following treatment. siRNA knockdown of each protein was used to assess their contribution to
the induction of CXCL8 expression following treatment of cells with HRV and CSE.
Results: We show that total expression of stabilizing/de-stabilizing proteins linked to CXCL8 regulation, including
AUF-1, KHSRP and HuR, are not altered by CSE, HRV or the combination of the two stimuli. Importantly, however,
siRNA-mediated knock-down of HuR, but not AUF-1 or KHSRP, abolishes the enhancement of CXCL8 by HRV+CSE.
Data were analyzed using one-way ANOVA with student Newman-Keuls post hoc analysis and values of p≤ 0.05
were considered significant.
Conclusions: Induction of CXCL8 by the combination of HRV and CSE is regulated by mRNA stabilization
involving HuR. Thus, targeting the HuR pathway may be an effective method of dampening CXCL8 production
during HRV-induced exacerbations of lower airway disease, particularly in COPD patients and asthmatic patients
who smoke.
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More than half of all exacerbations of asthma and COPD
are associated with viral infections, with HRV being the
dominant viral pathogen detected [1]. In vivo, the airway
epithelium is the primary site of HRV infection but
infection does not induce any obvious cytopathic effects
in epithelial cells. Rather, it is now generally thought that
HRV alters epithelial cell biology in a manner which results
in a virally-induced enhanced inflammatory state [2,3]. In
support of this, it is well established that HRV infection of
human bronchial epithelial cells, both in vivo and in vitro,
triggers the release of a variety of pro-inflammatory and
host-defence genes [3,4].
Cigarette smokers experience more frequent upper
respiratory infections that both last longer and are
more severe, when compared to non-smokers [5-8].
Moreover, cigarette smoke generally impairs innate im-
mune responses [9-13], including during viral infections
with influenza [14-18] or respiratory syncytial virus [19,20].
Approximately a quarter of patients with asthma smoke,
and these individuals have worse respiratory symptoms,
require more hospitalizations and are less responsive to
anti-inflammatory treatments than asthmatic patients
who do not smoke [21,22]. Cigarette smoking is the
dominant risk factor associated with the development
and progression of COPD. Taken together, these obser-
vations suggest that HRV infection in COPD patients,
and in asthmatic patients who smoke, would lead to
substantially worse clinical outcomes and exacerbations
compared to their non-smoking counterparts.
There is now growing evidence that CSE modulates
HRV induced expression of many inflammatory, antiviral
and host defence genes in airway epithelial cells [23-26].
Although in many cases, CSE down-regulates HRV-induced
epithelial gene expression, this is not the case for the potent
neutrophil chemoattractant, CXCL8 [23,24]. Rather, we have
shown that HRV and CSE each alone induce production of
CXCL8 and the combined stimulus induces at least additive
production of CXCL8 from human bronchial epithelial
cells [24]. This may have important consequences as levels
of CXCL8 have been shown to correlate with symptom
severity during HRV infections [27]. Moreover, not only
do neutrophil numbers in sputum correlate with disease
severity in patients with COPD [28], but neutrophil num-
bers and neutrophil degranulation correlate with disease
severity during viral exacerbations of asthma and COPD
[29,30]. In addition, increased sputum levels of CXCL8 are
associated with neutrophilic inflammation in asthmatics
who smoke [22].
We have shown that the enhancement of HRV-induced
epithelial CXCL8 production by CSE is due, at least in
part to mRNA stabilization [24]. It is well established that
stability of mRNA encoding CXCL8 can be regulated via
effects at adenine/uridine-rich elements (AREs) present inthe 3’ UTR of CXCL8 mRNA [31,32]. Four elements com-
posed of AUUUA are present in the proximal portion of
the CXCL8 3’ UTR, two of which are overlapping [33-35].
CXCL8 mRNA stability has been shown to be regulated
via the p38 MAPK pathway [35-37] and we have shown
that the combination of HRV+CSE induces activation of
the p38 MAPK pathway and that inhibition of this path-
way attenuates the additive enhancement of CXCL8 by
HRV+CSE compared to either treatment alone [24].
Several mRNA stabilizing/destabilizing proteins have
been reported to be involved in regulating the degradation
rate of CXCL8 mRNA, depending on the cell type and
stimuli studied, with no overall consensus of which is
the dominant factor involved in mRNA stability of this
gene. These include AUF-1 [33], KHSRP [38,39], HuR
[33-35,38] and tristetraprolin (TTP) [23,34]. HuR is in-
volved in stabilizing mRNA, KHSRP and TTP both
destabilize mRNA, while AUF-1, which has four isoforms
and has been shown to both stabilize and destabilize
mRNA transcripts [40]. To date none of these proteins
have specifically been linked to CSE-induced stabilization
of CXCL8. Moreover, the mechanisms responsible for
regulating mRNA stabilization in epithelial cells exposed
to HRV and CSE are unknown. We hypothesized that the
enhancement of HRV-induced CXCL8 by CSE is regulated
via the actions of one or more of these proteins, and the
current study was performed to test this hypothesis.
Methods
Materials
The following reagents were purchased from the indicated
suppliers: bronchial epithelial cell basal medium and addi-
tives to create serum-free bronchial epithelial cell growth
medium (BEGM) (Lonza, Walkersville, MD); WI-38 cells
and HRV type 16 (American Type Culture Collection,
Manassas, VA); 3R4F research grade cigarettes (College of
Agriculture Reference Cigarette Program, University of
Kentucky) firefly luciferase reporter plasmid pGL4.10[luc2]
and passive lysis buffer (Promega, Madison, WI); fire-
fly luciferase assay kit (Biotium Inc., Hayward, CA);
TransIT-LT1 transfection reagent (Mirus, Madison, WI);
anti-AUF-1 antibody (#07-260, Upstate curtsey of EMD
Millipore, Billerica, MA); anti-KHSRP antibody (#Ab83291,
Abcam, Toronto, ON, Canada); anti-HuR antibody
(#A-21277, Molecular Probes courtesy of Life Technologies,
Burlington, ON, Canada); glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) antibody (AbD Serotec, Raleigh,
NC); horseradish peroxidase (HRP)-conjugated anti-
mouse antibody (Jackson ImmunoResearch Laboratories,
West Grove, PA); HRP-conjugated anti-rabbit antibody
(GE Healthcare Biosciences, Piscataway, NJ); enhanced
chemiluminescent (ECL) substrate reagent (GE Healthcare
Biosciences, Piscataway, NJ); Lowry DC protein assay
(Biorad Laboratories, Mississauga, ON); recombinant
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targeting AUF-1 (S100300454 and S102653665), KHSRP
(S100300587 and S100054691) and HuR (S100300139
and S103246551) (Qiagen, Toronto, ON, Canada); medium
GC negative control non-targeting siRNA, OptiMEM
reduced serum media and Lipofectamine RNAiMAX
transfection reagent (Invitrogen, Burlington, ON, Canada).
All other chemicals were purchased from Sigma-Aldrich
(Oakville, ON, Canada).Epithelial cell culture
Primary human bronchial epithelial (HBE) cells were
derived using previously described methods [41]. Briefly,
cells were obtained via protease digestion of dissected air-
ways from normal non-transplanted human lungs obtained
from a tissue retrieval service (International Institute for
the Advancement of Medicine (IIAM), Edison, NJ). Ethical
approval to receive and utilize lung tissues was obtained
from both the Conjoint Health Research Ethics Board
of the University of Calgary (Calgary, AB) and from the
Internal Ethics Board of IIAM (Edison, NJ). No personal
identifying information was provided for any of the donors.
For these studies, cells were derived from 6 individual lung
donors. Five donors were male and ages ranged from 20 to
62 years. All subjects died of head trauma or from cerebro-
vascular causes. HBE cells were cultured in BEGM at 37°C
in 5% CO2. Prior to experimental treatments, cells were
cultured overnight in BEGM from which hydrocortisone
was removed (BEGM no HC), and then that medium was
used for subsequent experiments.Preparation of purified HRV and CSE
HRV-16 stocks were propagated in WI-38 fibroblast
cells and purified by density centrifugation on a sucrose
cushion as previously described [42]. CSE was prepared
according to previously described methods [24]. Briefly,
CSE was generated by bubbling one 3R4F research grade
cigarette into 4 mL of BEGM without hydrocortisone at
a rate of 5 min per cigarette using a syringe apparatus.
The resulting solution was filtered through a 0.22 μm
filter to remove bacteria and/or large particles and
subsequently adjusted with medium to an absorbance
reading of 0.15 at 320 nm. This was arbitrarily defined
as 100% CSE. Based on previous viability studies, CSE
concentrations at or below an absorbance reading of
0.075 did not affect cell viability of HBE cells as
assessed by the MTT viability assay [24]. Therefore, we
used 50% CSE (absorbance of 0.075 at 320 nm) for all
exposures in the current study. This final dilution of
CSE applied to cells represented a 1:20 final dilution of
the original 4 ml extract, and represents approximately
1/80th of the soluble components of a single cigarette
per well of a 6-well plate.HRV infection and CSE treatment
HBE cells were infected with 105.5 tissue culture-infective
dose U/ml (multiplicity of infection ~1.0) of purified
HRV. Cells were treated with CSE alone, HRV alone or
with CSE and HRV together, and were then incubated at
34°C in 5% CO2.
Lactate dehydrogenase (LDH) assay
The viability of cells was also assessed using the
Cyto96™ LDH assay according to the manufacturer’s in-
structions. Data were expressed as percent cytotoxicity
of HBE cells following treatment with CSE alone, HRV
alone or HRV+CSE compared to HBE cells treated with
medium alone.
siRNA transfections
Sub-confluent HBE cells were used for transient siRNA
transfections. Individual siRNAs were diluted in serum-
free OptiMEM media and transfected using Lipofectamine
RNAiMAX reagent according to the manufacturer’s
specifications. Transfection reagent only, and non-targeting
siRNA controls were used for each treatment. HBE cells
were treated with 1:4 siRNA-transfection lipid mixture
and 3:4 BEGM without antibiotics (no PSF, gentamicin or
amphotericin) with a final siRNA concentration of either
10nM (HuR and KHSRP) or 30nM (AUF-1) siRNA and
incubated for 24 h at 37°C and 5% CO2. The supernatant
was then aspirated and cells were recovered in BEGM no
HC for 24 h at 37°C and 5% CO2. Following recovery, cells
were subject to the desired treatment for an additional 24
h at 34°C and 5% CO2.
Western blotting and ELISAs
Following appropriate treatments, supernatant was re-
moved and cells were lysed with ice-cold lysis buffer
(1% Triton X-100 in 1X MES buffered saline pH 7.4,
anti-protease tablets, 50 nM sodium orthovanadate, 0.4M
sodium pyrophosphate, 1M sodium fluoride and 100mM
phenylmethanesulfonylfluoride). Cells were scraped off
the plate, frozen overnight to enhance cell lysis, and
centrifuged. Total protein concentration in cell lysates was
quantified using the Lowry DC protein assay (Bio-Rad,
Mississauga, ON, Canada). Equivalent amounts of each
sample (10 μg total protein) were separated by SDS-PAGE
and proteins were then transferred to a 0.45 μm nitrocel-
lulose membrane. Membranes were blocked with 5% skim
milk for 1 h and incubated with an appropriate dilution of
specific primary antibody (1:1000 for anti-AUF-1, 1 μg/mL
for anti-KHSRP and anti-HuR) at 4°C overnight. Mem-
branes were then washed, incubated with either HRP-
conjugated anti-mouse (1:2000 following anti-HuR) or
anti-rabbit (1:1000 following anti-AUF-1 and 1:10,000
following anti-KHSRP) secondary antibody for 1 h, washed
again and developed using ECL substrate reagent.
Figure 1 CSE alone, HRV alone, or HRV+CSE do not affect HBE
cell viability. HBE cells were treated with medium (control), CSE,
HRV or the combination for 24h prior to viability assessment using
the LDH assay. Data are presented as mean ± SEM (n=3).
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housekeeping gene GAPDH confirmed equal loading
of protein. Densitometric analysis was performed using
ImageJ software (version 1.41, National Institute of Health,
Bethesda, MD, USA). Percent expression of the protein of
interest was assessed by comparison to the appropriate
control and normalized for minor protein loading variation
to GAPDH levels.
Secreted CXCL8 was assessed in cell supernatants by
ELISA assay using previously described methods [4]. The
minimum level of detection for CXCL8 was 30pg/mL.
Statistical analysis
Normal distribution of data was assessed using the
Kolmogorov-Smirnov normality test. Data were analyzed
using one-way ANOVA with student Newman-Keuls post
hoc analysis. Values of p≤ 0.05 were considered significant.
Results and discussion
CSE alone, or in combination with HRV, does not affect
HBE cell viability
We have previously shown that the concentration of
CSE utilized for these studies, either alone or in combin-
ation with HRV, does not affect HBE cell viability as
assessed by the MTT assay [24]. Here, we confirmed that
cell viability was also unaffected as assessed via the LDH
assay in HBE cells treated with CSE alone, HRV alone or
HRV+CSE (Figure 1).
Expression levels of mRNA stabilizing/destabilizing
proteins AUF-1, KHSRP and HuR are not altered by CSE,
HRV or HRV+CSE at early time-points
To investigate the roles of the mRNA stabilizing/de-
stabilizing proteins that have been previously linked
to CXCL8 mRNA stabilization, we first determined
whether the expression of these proteins was altered
in primary HBE cells stimulated with CSE alone, HRV
alone or HRV+CSE. Using the actinomycin D chase assay,
mRNA stabilization of CXCL8 by HRV+CSE was observed
within 3 h post-treatment [24]. Therefore, we examined the
expression of these stabilizing/destabilizing proteins at early
time-points, as this would be the most relevant time-frame
to affect the stabilization of CXCL8 mRNA. Although
there was constitutive expression of AUF-1 (Figure 2A),
KHSRP (Figure 2B) and HuR (Figure 2C) at 30 min, 1 h
and 3 h, none of the treatments visually affected the ex-
pression level of these proteins in HBE cells at the
time-points studied. Moreover, there was no significant
difference in expression levels of these proteins as
assessed by densitometry (Figure 2A-C). Examination
of AUF-1 and HuR expression at later time-points,
including 6 and 9 h post treatment with CSE, HRV or
HRV+CSE resulted in similar observations, with no
difference in expression levels of these proteins followingtreatment (data not shown). Using three different anti-
bodies, we were unable to detect TTP protein in the HBE
cells, either constitutively or following any of the treat-
ments; therefore it is unlikely that the expression of TPP
would be contributing to CXCL8 gene regulation by
HRV+CSE. Two of these antibodies readily detected
stimulus-induced TTP in the bronchial epithelial BEAS-
2B cell line (data not shown). In contrast to our data in
primary HBE cells derived from normal subjects, TTP has
been shown to be expressed at very low levels in cystic
fibrosis lung epithelial cells at rest. Upon stimulation it
has been shown to regulate CXCL8 mRNA expression in
these cells [43,44]. The discrepancy in these results could
be attributed to the use of cystic fibrosis cells as opposed
to epithelial cells derived from normal individuals, as it is
possible that TTP expression is enhanced to detectable
levels in disease states. Collectively, these data imply that,
if AUF-1, KHSRP or HUR are involved the enhancement
of HRV-induced CXCL8 by CSE in HBE cells, it is not via
modulation of their expression levels.
Figure 2 CSE, HRV, or HRV+CSE do not alter AUF-1, KHSRP and HuR expression in HBE cells. HBE cells were treated with medium
(control), CSE, HRV or the combination for the times indicated. Total cell lysates were harvested and analyzed via immunoblotting. Membranes
were probed with specific AUF-1 (A), KHSRP (B) or HuR (C) antibodies, then were subsequently stripped and re-probed with an antibody to
GAPDH to ensure equal protein loading. Data are representative of 3 separate experiments. Relative expression levels of each protein of interest
from the 3 experiments were assessed by densitometry.
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via HuR
Although expression levels of AUF-1, KHSRP or HuR were
not altered, it remained possible that treatment with CSE,
HRV or HRV+CSE could affect the functions of these
proteins within the cell. The activity of TTP, KHSRP and
HuR all can be regulated by phosphorylation [45-47]. Un-
fortunately, there are no currently available commercial
antibodies which selectively identify post-translational mod-
ifications of AUF-1, KHSRP or HuR. To further assess therole of these stabilizing/destabilizing proteins in enhance-
ment of HRV-induced CXCL8 by CSE, we used an alterna-
tive approach utilizing siRNA to target the knock-down of
each of AUF-1, KHSRP and HuR. As a reference to com-
pare effects of siRNA knockdown on levels of CXCL8, the
levels produced by the same cell preparations exposed to
HRV alone, CSE alone or the combination of the two, are
shown in Figure 3. This data also confirms our previously
published results in HBE cells obtained from an additional
6 primary cell donors [24].
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ferent siRNA duplexes targeting either AUF-1 (Figure 4),
KHSRP (Figure 5) or HuR (Figure 6). Appropriate con-
trols were performed in parallel; including treatment
with medium alone, mock transfection with the transfec-
tion lipid alone, and transfection with the appropriate
concentration of a non-targeting control siRNA, as not all
siRNAs were effective at the same concentration. Cells
were recovered for 24 h prior to an additional 24 h treat-
ment with HRV+CSE. Initial studies focused on validation
of respective protein knockdown. Although there was basal
expression of AUF-1, KHSRP and HuR in HBE cells, we
confirmed siRNA knock-down following our treatment of
interest (HRV+CSE) in order to ensure that this treatment
was not limiting the ability of the siRNAs to successfully
produce knockdown. For all siRNA validation experiments
(Figures 4A, 5A and 6A), similar levels of knockdown wereFigure 3 CXCL8 protein is enhanced by HRV+CSE compared to
CSE or HRV alone in HBE cells. HBE cells from 6 HBE cell donors to
be used for siRNA experiments were treated with medium control,
CSE, HRV or HRV+CSE for 24 h and cell supernatants were assessed
for CXCL8 protein release. Data are presented as mean ± SEM (n=6).
Asterisks denote a significant difference between the specified
treatments (*** p<0.001).
Figure 4 Effects of AUF-1-targeting siRNA on CXCL8 protein
expression in HBE cells. HBE cells were treated for 24 h prior to
harvesting cell supernatants for analysis with ELISA and whole cell
lysates for analysis with immunoblotting. To determine the level of
AUF-1 protein knock-down membranes were probed with a specific
AUF-1 antibody recognizing 4 isoforms of AUF-1, then were
subsequently stripped and re-probed with an antibody to GAPDH to
ensure equal protein loading (A; representative of 3 separate
experiments). Densitometry analysis with % knock-down relative to
HRV+CSE alone is also shown for each isoform of AUF-1 (A; n=3).
Supernatants were analyzed for CXCL8 protein (B; n=3). Data are
presented as mean ± SEM. Lipid denotes transfection reagent alone.
NT denotes non-targeting control siRNA. ns = not significant.observed in cells treated with medium alone, CSE alone or
HRV alone (data not shown).
The AUF-1 gene is expressed as four alternatively
spliced products with differing molecular weights, including
37, 40, 42 and 45 kDa isoforms. Neither the transfection
reagent alone nor the control non-targeting siRNA (30 nM)
had a significant effect on protein expression of any AUF-1
isoform (Figure 4A). Despite using AUF-1-targeting siRNA
duplexes from two different suppliers targeting different
regions of the molecules, we were unable to effectively
knockdown all four AUF-1 isoforms. The reasons for this
are unclear. Each of the two siRNAs targeting AUF-1 was
Figure 5 Effects of KHSRP-targeting siRNA on CXCL8 protein
expression in HBE cells. HBE cells were treated for 24 h prior to
harvesting cell supernatants for analysis with ELISA and whole cell
lysates for analysis with immunoblotting. To determine the level of
KHSRP protein knock-down membranes were probed with a specific
KHSRP antibody, then were subsequently stripped and re-probed
with an antibody to GAPDH to ensure equal protein loading
(A; representative of 3 separate experiments). Densitometry analysis
with % knock-down relative to HRV+CSE alone is also shown
(A; n=3). Cell supernatants were analyzed for CXCL8 protein
(B; n=5). Data are presented as mean ± SEM. Lipid denotes
transfection reagent alone. NT denotes non-targeting control siRNA.
Asterisks denote a significant difference between the specified
treatments (**p<0.01). ns = not significant.
Figure 6 Effects of HuR-targeting siRNA on CXCL8 protein
expression in HBE cells. HBE cells were treated for 24 h prior to
harvesting cell supernatants for analysis with ELISA and whole cell
lysates for analysis with immunoblotting. To determine the level
of HuR protein knock-down membranes were probed with a
specific HuR antibody, then were subsequently stripped and
re-probed with an antibody to GAPDH to ensure equal protein
loading (A; representative of 3 separate experiments).
Densitometry analysis with % knock-down relative to HRV+CSE
alone is also shown (A; n=3). Cell supernatants were analyzed for
CXCL8 protein (B; n=6). Data are presented as mean ± SEM. Lipid
denotes transfection reagent alone. NT denotes non-targeting
control siRNA. Asterisks denote a significant difference between
the specified treatments (***p<0.001).
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the 45 kDa isoform of AUF-1. Densitometry calculations
showed that the knockdown of the 45 kDa isoform was
around 90% with each of the two siRNAs while knockdown
of the other three isoforms was not as efficient (Figure 4A).
Next, CXCL8 protein levels were measured from su-
pernatants collected from HBE cells treated with these
siRNAs. No significant differences were observed between
HRV+CSE treated cells after pre-treatment with medium,
transfection lipid alone or either of the two AUF-1 siRNA
duplexes (Figure 5B). Although AUF-1 has been shown to
associate with CXCL8 mRNA in human saliva [33], these
data suggest that the 45 kDa isoform of AUF-1 is notinvolved in the stabilization of CXCL8 mRNA following
treatment with HRV+CSE, but no firm conclusions can be
drawn regarding the other isoforms. The 45 and 40 kDa
isoforms of AUF-1 are purported to be involved in de-
stabilizing mRNA, while the 42 and 37 kDa isoforms
are involved in stabilizing mRNA [40]. Since there was
a very strong basal expression of the 42 kDa isoform of
AUF-1, it is unfortunate we were unable to knockdown
this isoform sufficiently to determine if it was contributing
to the stabilization of CXCL8 mRNA.
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siRNA (10 nM) did not have any significant effect on
protein expression of KHSRP (Figure 5A). Each of the two
siRNAs targeting KHSRP were significantly able to knock-
down the expression of KHSRP protein, as assessed by
densitometry, with a 61% and 78% knock-down compared
to HRV+CSE alone (Figure 5A). CXCL8 protein level
measurements revealed that KHSRP knockdown did not
reverse the enhancement of HRV-induced CXCL8 by CSE
(Figure 5B). One of the two siRNA duplexes had a slight,
but significant, effect on enhancing CXCL8 protein levels
in cells treated with HRV+CSE. Accordingly, KHSRP may
be involved in dampening the expression of CXCL8, but
since only one of the two siRNAs had this affect, this
result is inconclusive. Although studies have shown that
KHSRP associates with the 3’ UTR of CXCL8 [38,39], and
is essential for rapid degradation of this transcript [39],
these data suggest that KHSRP is not involved in the en-
hancement of HRV-induced CXCL8 by CSE. Nonetheless,
it is still possible that KHSRP may be involved in globally
dampening CXCL8 protein expression.
Transfection reagent alone or the control non-targeting
siRNA (10 nM) also did not have any significant effect on
protein expression of HuR (Figure 6A). Each of the two
siRNAs targeting HuR were significantly able to knock-
down the expression of HuR protein as assessed by
densitometry, with a 68% and 70% knockdown compared
to HRV+CSE alone (Figure 6A). CXCL8 protein level mea-
surements revealed that HuR knock-down, using each of
two different HuR-targeting siRNA duplexes, did have a
significant effect on CXCL8 protein expression from HBE
cells following treatment with HRV+CSE (Figure 6B).
CXCL8 protein expression was reduced to levels observed
with treatment of HBE cells with HRV alone (Figure 3).
Compared to medium alone, HRV alone induced CXCL8
protein levels to 9.5 ± 2.4 ng/mL (Figure 3). The combin-
ation of HRV+CSE induced CXCL8 protein levels to levels
above 15 ng/mL (Figures 3 and 6B). Levels of CXCL8
protein released from HBE cells following treatment with
HRV+CSE in conjunction with HuR-targeting siRNA #1
or siRNA #2 were 8.9 ± 1.6 ng/mL and 9.0 ± 1.5 respect-
ively. These data suggest that HuR is involved in stabil-
izing CXCL8 mRNA when HBE cells are treated with
HRV+CSE, leading to elevated protein levels compared
to cells treated with HRV alone.
In order to determine whether HuR knockdown had an
effect on basal CXCL8 protein levels, or those induced by
CSE or HRV treatment alone, we repeated these experi-
ments with all four treatments. Since AUF-1 and KHSRP
knockdown did not appear to play a role in HRV+CSE-
induced CXCL8 we did not feel it was pertinent to extend
these studies to include siRNAs targeting the knockdown
of these proteins. Each of the two siRNAs targeting HuR
were able to knockdown the expression of HuR proteincompared to control medium, CSE, HRV and HRV+CSE
alone (Figure 7A). Again, transfection reagent alone or the
control non-targeting siRNA (10 nM) also did not have any
significant effect on protein expression of HuR (Figure 7A).
CXCL8 protein level measurements revealed that HuR
knock-down, using each of two different HuR-targeting
siRNA duplexes, did not have a significant effect on basal,
CSE-induced or HRV-induced CXCL8 protein expression,
while it did have a significant effect on CXCL8 protein ex-
pression following treatment with HRV+CSE (Figure 7B).
Collectively, these data suggests that HuR is only in-
volved in stabilizing CXCL8 protein induced by the
combined treatment of HRV+CSE but not the induction
of CXCL8 by either treatment alone. This is consistent
with our earlier observations that stabilization of CXCL8
mRNA decay was only observed with the combination of
HRV+CSE [24]. Since CXCL8 expression can be regulated
via a number of mechanisms, the induction of CXCL8 by
CSE alone and HRV alone could be explained via effects
at other levels than mRNA stabilization. Indeed, we have
previously shown using transiently transfected CXCL8
promoter-luciferase constructs in the BEAS-2B bronchial
epithelial cell line that HRV induces activation of the
CXCL8 promoter [48]. It also should be noted that, since
siRNA targeting HuR resulted only in partial knockdown
of this protein, our data likely underrepresent the contri-
bution of HuR to the stabilization of CXCL8 mRNA upon
treatment with HRV+CSE.
In support of HuR playing a role in stabilizing CXCL8,
HuR has been shown to associate with CXCL8 mRNA
in human saliva [33], in monocytic THP-1 cells following
stimulation with nitric oxide [34] and following an in-
flammatory stimulus in the BEAS-2B bronchial epithelial
cell line [49]. Winzen and colleagues also show that
CXCL8 mRNA is stabilized through the 3’ UTR via HuR
[35]. It has also been demonstrated that both HuR and
KHSRP associate with the 3’ UTR of CXCL8 but, at least
in breast cancer cells following IL-1β treatment, there was
a much greater association of the stabilizing factor HuR
than the destabilizing factor KHSRP [38]. Since we did not
see a role for KHSRP in stabilizing HRV+CSE-induced
CXCL8, it is likely that HuR is also the main contributing
factor in the stabilization of CXCL8 mRNA. Thus, our
data add to the growing body of literature that HuR is one
of the most important stabilizing factors involved in
stabilizing CXCL8 mRNA in various cells types following
a variety of treatments.
We recognize that our study is not without limitations.
Although, CSE was used in our study rather than direct
gaseous cigarette smoke exposure, CSE has been exten-
sively used as a model for cigarette smoke exposure in tis-
sue culture [23-26,50-52], and it is reasonable to assume
that CSE mimics the soluble component of direct cigarette
smoke exposure in the airway surface fluid of the lung
Figure 7 HuR knockdown affects HRV+CSE-induced, but not basal, CSE or HRV-induced CXCL8 protein expression in HBE cells.
HBE cells were treated for 24 h prior to harvesting cell supernatants for analysis with ELISA and whole cell lysates for analysis with immunoblotting.
To determine the level of HuR protein knock-down membranes were probed with a specific HuR antibody, then were subsequently stripped and
re-probed with an antibody to GAPDH to ensure equal protein loading (A; representative of 3 separate experiments). Cell supernatants were
analyzed for CXCL8 protein (B; n=3). Data are presented as mean ± SEM. Lipid denotes transfection reagent alone. NT denotes non-targeting control
siRNA. Asterisks denote a significant difference between the specified treatments (*p≤0.05, **p<0.01 and ***p<0.001). ns = not significant.
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posure to CSE may also not be completely reflective of the
effects that chronic cigarette smoking has on the human
airway epithelium in vivo, and we acknowledge that this is
also a limitation of our study. In order to address some of
these concerns, and to confirm our in vitro findings in vivo,
we are currently performing a study using experimental
HRV infections in human volunteers, comparing responses
in otherwise healthy smokers and healthy non-smokers. Ex-
pression of CXCL8, as well as the mechanisms involved in
its regulation will be one of the outcomes to be evaluated.
Conclusions
We have previously reported that CSE alone and HRV
alone each induce the production of CXCL8 from human
bronchial epithelial cells and that when the two stimuli
are combined there is at least an additive enhancement of
CXCL8 compared to either treatment alone [24]. The en-
hancement of HRV+CSE-induced CXCL8 is regulated, at
least in part, at the level of mRNA stability. Our previous
studies together with our current observations provide the
first demonstration that the enhanced production of CXCL8
from human airway epithelial cells exposed to the combin-
ation of HRV and CSE is regulated post-transcriptionally via
mRNA stabilization and that HuR plays a key role in thisprocess. If enhancement of CXCL8 by the combination of
HRV infection and cigarette smoking is seen in vivo, un-
derstanding of the mechanisms behind this enhancement
would aid in developing adequate treatments to limit the
over-exuberant pro-inflammatory response that leads
to increased neutrophil recruitment. Although not all
genes regulated by HuR may be involved in the recruit-
ment of neutrophils, it has been shown that HuR also
associates with the 3’UTR of TNF-α+IFN-γ-induced
neutrophil chemokines CXCL1 and CXCL2 in human
airway epithelium [49]. Although the expression levels
of these particular chemokines have not been investi-
gated following treatment of airway epithelial cells
with HRV+CSE, CXCL1 has been shown to be induced
by HRV alone. If CXCL1 and/or CXCL2 are enhanced
following HRV+CSE treatment, it is possible that HuR
may be involved in this process and this offers a future
avenue for investigation. Together, this study suggests
that inhibition of HuR, either directly or via a pathway
that increases its activation/cellular localization, may
help in reducing airway epithelial production of CXCL8,
limiting the excessive recruitment of neutrophils. This
would be applicable not only in HRV-infected smokers
but particularly in COPD patients and smoking asth-
matics during HRV-induced exacerbations.
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